Want to see HK:2511 full AI Analyst Report?
2511 Stock Chart & Stats
HK$3.05
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$3.05
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.80 - HK$4.72
Previous CloseN/A
Volume82.00K
Average Volume (3M)599.41K
Market Cap
HK$2.09B
Enterprise ValueHK$1.17K
Total Cash (Recent Filing)HK$326.36M
Total Debt (Recent Filing)HK$154.73M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding670,035,640
10 Day Avg. Volume907,600
30 Day Avg. Volume599,410
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.14
Price to Sales (P/S)0.00
P/FCF Ratio-7.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.60Price Target Upside83.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.56
Revenue Forecast (FY)HK$3.00B
Bulls Say, Bears Say
Bulls Say
Balance-sheet RepairThe return to positive equity and more manageable leverage represents meaningful balance-sheet repair from 2021–2022. This improves financial resilience and may provide greater flexibility to fund development, although the benefit depends on reducing continuing losses and cash consumption.
Improving Free Cash Flow TrendAlthough free cash flow remains negative, the improvement in 2025 suggests some moderation in cash outflows compared with 2023–2024. If sustained, a lower burn rate could extend funding runway and reduce the pace at which the company must seek external capital.
Reported EPS GrowthThe reported positive EPS-growth measure indicates improvement in the earnings metric despite the company remaining loss-making. Continued progress could support operating leverage over time, but its durability remains dependent on translating development activity into revenue and narrower losses.
Bears Say
No Reported RevenueZero reported revenue means the company has not yet demonstrated commercial monetization of its therapeutic development activities. This leaves future funding and value creation dependent on achieving commercialization or meaningful revenue generation, with limited current operating leverage.
Persistent Operating LossesRecurring EBIT and net income losses indicate that the business currently lacks a profitable operating base. Continued losses can delay self-sustaining growth, constrain capital allocation, and increase dependence on successful development milestones before earnings can become durable.
Ongoing Cash BurnPersistent negative operating and free cash flow shows that current activities consume rather than generate cash. Reliance on external funding creates an ongoing financing requirement and can limit strategic flexibility if losses persist or capital becomes less available.
Hightide Therapeutics Inc News
2511 FAQ
What was Hightide Therapeutics Inc’s price range in the past 12 months?
Hightide Therapeutics Inc lowest stock price was HK$1.80 and its highest was HK$4.72 in the past 12 months.
What is Hightide Therapeutics Inc’s market cap?
Hightide Therapeutics Inc’s market cap is HK$2.09B.
When is Hightide Therapeutics Inc’s upcoming earnings report date?
Hightide Therapeutics Inc’s upcoming earnings report date is Mar 26, 2027 which is in 173 days.
How were Hightide Therapeutics Inc’s earnings last quarter?
Hightide Therapeutics Inc released its earnings results on Aug 31, 2026. The company reported -HK$0.327 earnings per share for the quarter.
Is Hightide Therapeutics Inc overvalued?
According to Wall Street analysts Hightide Therapeutics Inc’s price is currently Undervalued.
Does Hightide Therapeutics Inc pay dividends?
Hightide Therapeutics Inc does not currently pay dividends.
What is Hightide Therapeutics Inc’s EPS estimate?
Hightide Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hightide Therapeutics Inc have?
Hightide Therapeutics Inc has 670,035,640 shares outstanding.
What happened to Hightide Therapeutics Inc’s price movement after its last earnings report?
Hightide Therapeutics Inc reported an EPS of -HK$0.327 in its last earnings report. Following the earnings report the stock price went up 3.583%.
Which hedge fund is a major shareholder of Hightide Therapeutics Inc?
Currently, no hedge funds are holding shares in HK:2511
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hightide Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.45%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Hightide Therapeutics Inc
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.
2511 Stock 12 Month Forecast
Average Price Target
HK$5.60
▲(83.61% Upside)
Technical Analysis
CANbridge Pharmaceuticals Inc.
―
Mabpharm Limited
―
SinoMab Bioscience Ltd.
―
Transcenta Holding Limited
―
Cutia Therapeutics
―